Diabetics got three Clinical Trials for the new medication in the last year or two
Diabetes is on the rise, and new clinical trials are underway in an attempt to offer assistance to sufferers across the globe. These three trials could change the way the disease is treated in the future. There are many different kinds of trials including the Paid Medical Trials from Trials 4 Us which allows people to get paid to help the medical industry as best as possible. Paid Medical Trials are a very clever way of getting the drug tested in a voluntary way and in a way that’s organized.
Oral Insulin
Novo Nordisk may not be alone in the pursuit of a diabetes drug that is taken orally, but they are currently initiating a Phase IIb trial for an oral insulation candidate. So far, trials have shown that the orally ingested drug reduces glucose levels over a 24-hour period – something that is crucial to diabetics. Oramed, as the drug has been named, will not replace injected insulin, but it does offer hope that oral insulin can be prescribed in earlier stages of the disease so that a lower dose of insulin is required as the disease progresses.
Ultra-Rapid Insulin
Currently, there is only one type of rapid insulin available on the market, and Novo Nordisk’s Fiasp can be taken two minutes before a meal or up to 20 minutes after and is still effective. This makes it easier for patients to control their sugar levels, as they don’t have to stress about times and making sure they plan accordingly. Now Eli Lilly and Company are trialing ultra-rapid insulin too, and LY00014 will be tested on both type 1 and type 2 diabetes.
This will be a critical trial for both diabetes types, as if another rapid-acting insulin becomes available, there will be more choice, and a greater number of drug companies may follow suit and release their own versions.
Oral Semaglutide
With the World Health Organization expressing concern at the rise in the number of diabetics, the focus on drugs to ease the suffering and making living with diabetes easier is at an all-time high.
Novo Norsk has completed the Adaptive Phase 1 Studies and has now entered stage 3 trials for a drug that is an analog that stimulates the pancreas, forcing it to produce insulin. Currently, this type of stimulant is only available by injection, but the newly developed oral semaglutide is not only long-lasting, but it also is easier to administer and absorbed far faster.
For those with diabetes, every new drug that reaches the market has the potential to change their lives for the better.